OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS)
$7.25 0 (0%)
Analysed OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) News Sources
Oxford Biomedica H1 Earnings Call Highlights
22-09-2026
marketbeat.com
Gene Transfer Technologies Market Size, Share & Trends Analysis to 2036 Featuring Profiles of Thermo Fisher Scientific, Lonza Group, Oxford Biomedica, FUJIFILM Diosynth Biotechnologies, Aldevron and More
23-09-2026
yahoo.com
How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients
25-09-2026
yahoo.com
Top 3 British Biotech Stocks To Watch In October 2026
10-10-2026
yahoo.com
OXB Appoints Joachim Kreuzburg as Independent Non-Executive Director
16-10-2026
yahoo.com
3 British Biotech Stocks With Market Caps Up To £4 Billion
17-10-2026
yahoo.com
What Investors Overlooked Before Oxford Biomedica Slid
21-10-2026
yahoo.com
3 British Biotech Stocks To Watch In October 2026
24-10-2026
yahoo.com
Hikma Pharmaceuticals And 2 British Biotech Stocks To Watch
31-10-2026
yahoo.com
Oxford BioMedica PLC (OXBDF) (H1 2026) Earnings Call Highlights: Revenue Climbs 10% as Client ...
24-09-2026
yahoo.com
What is the current price of OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS)?
The current price of OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) is $7.25.
OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) since the previous trading day is $0.
OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) since the previous trading day is 0%.
What is the most recent average sentiment score for OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS)?
The most recent average sentiment score for OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) is 79 out of 100.
What is the most recent average sentiment for OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS)?
The most recent sentiment for OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS) is .
SEC-8K** Filing Available For OXFORD BIOMEDICA PLC (OXBDF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.